Abbott Laboratories vs. Crescent Biopharma, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 8 of 8 compared factors.
Size & Scale
| ABT | CBIO | |
|---|---|---|
| Market Cap | $177.12 billion | $622.95 million |
| Revenue (TTM) | $46.59 billion | $119.38 million |
| Net Income (TTM) | $5.42 billion | $-20,897,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | CBIO | |
|---|---|---|
| P/E Ratio | 33.08 | — |
| Price / Book | 3.42 | 4.37 |
| Price / Sales | 3.80 | 5.22 |
ABT leads on 2 of 2 valuation factors.
Profitability
| ABT | CBIO | |
|---|---|---|
| Net Margin | 11.65% | -17.50% |
| Return on Equity | 10.48% | -14.67% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | CBIO | |
|---|---|---|
| Dividend Yield | 2.47% | — |
| Payout Ratio | 81.55 | — |
ABT and CBIO split the dividend factors evenly.
Risk & Sentiment
| ABT | CBIO | |
|---|---|---|
| Short Interest | 0.57% | 1.64% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, CBIO overview, CBIO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.